健骨康胶囊治疗绝经后骨质疏松症临床观察

Clinical Study of Jiangukang Capsule on Postmenopausal Osteoporosis

目的：观察院内制剂健骨康胶囊对绝经后骨质疏松性骨痛症186例的临床疗效。方法：将186例符合入选条件的患者随机分为2组。治疗组94例和对照组92例，治疗组给予健骨康胶囊4粒／次，每日3次，口服；对照组钙尔奇D1粒／次，每日2次，口服。疗程6个月。结果：两组患者治疗后3～6个月BMD都较治疗前有不同程度增高。以total为显著（增幅2．95％～4．40％），P〈0．01；治疗后两组BMD比较无显著意义。治疗组中54例患者疼痛症状得到显著改善，27例患者轻度改善，总改善率86．17％；对照组显著改善21例，轻度改善29例，总改善率54．35％。两组总改善率经统计学处理有显著差异P＜0．05，进一步经ridit分析显示治疗组疗效明显优于对照组。结论：健骨康胶囊对治疗绝经后骨质疏松症有提高骨密度（BMD），缓解骨痛之效果。

Objective： To observe the clinical curative effect of the Jiangukang Capsule （JGKC） made by our hospital on 186 patients with postmenopausal osteoporosis （PO）. Methods： One hundred and eighty--six patients with PO were randomly divided into 2 groups： 94 in the treatment group and 92 in the control group. Patients in the treatment group were given 4 capsules each time and thrice a day while patients in the control group were given 1 Caltrate pill each time and twice a day. The cause of treatment lasted 6 months. Results： The bone mineral density （BMD） of the patients in both groups increased in varying degree after 3--6 months of treatment but there was no significant difference between the two groups. Among the treatment group, pain symptoms were apparently improved in 54 cases and slightly improved in 27 cases. The total im- provement rate was 86.17%. Whereas pain symptoms were apparently improved in 21 cases and slightly improved in 29 cases in the control group with the total improvement rate 54.35%. The difference of total improvement rate between both groups was statistically significant （P〈0.05）. And with futhur ridit analysis, the curative effect in the treatment group was much better than that in the control group. Conclusion.. JGKC was able to increase the BMD and relieve the pain for the patients with PO.